U.S. Product Sales (in millions)
|
| Rituxan |
Avastin |
| Rituxan® (Rituximab) is an anti-CD20 antibody which we
commercialize with Biogen Idec
Inc. It is approved for several
forms of CD20-positive, B-cell
non-Hodgkin's lymphoma. In
2006, we also received approval
for Rituxan in combination with
methotrexate for reducing signs
and symptoms in adult patients
with moderately-to-severely
active rheumatoid arthritis who
have had an inadequate response
to one or more tumor necrosis
factor antagonist therapies. |
|
| Avastin® (bevacizumab) is an anti-VEGF humanized antibody approved for use in combination with intravenous 5-fluorouracil-based chemotherapy as a treatment for patients with first- or second-line metastatic cancer of the colon or rectum. It is also approved for use in combination with carboplatin and paclitaxel chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer. |
|
| |
|
| Herceptin |
Xolair |
| Herceptin® (Trastuzumab) is a humanized anti-HER2 antibody approved for use as a first-line therapy in combination with paclitaxel and as a single agent in second- and third-line therapy for patients with HER2-positive metastatic breast cancer. In 2006, we also received approval for Herceptin as an adjuvant treatment in HER2-positive, node-positive breast cancer as part of a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel. |
|
| Xolair® (Omalizumab for Subcutaneous
Use) is a humanized anti-IgE
antibody which we commercialize
with Novartis Pharma AG. Xolair
is approved for adults and adolescents
(12 years of age and above)
with moderate-to-severe persistent
asthma who have a positive
skin test or in vitro reactivity to a
perennial aeroallergen and whose
symptoms are inadequately controlled
with inhaled corticosteroids. |
|
| |
|
| Tarceva |
Lucentis |
| Tarceva® (erlotinib) monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Tarceva in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer. |
|
| Lucentis® (ranibizumab injection)
is an anti-VEGF antibody fragment
approved for the treatment of neovascular
(wet) age-related macular
degeneration. |
|
| Nutropin Products |
Thrombolytics |
| Nutropin® (somatropin [rDNA origin] for injection) and Nutropin AQ® (somatropin [rDNA origin] injection) are growth hormone products approved for the treatment of growth hormone deficiency in children and adults, growth failure associated with chronic renal insufficiency prior to kidney transplantation, short stature associated with Turner syndrome, and long-term treatment of idiopathic short stature. |
|
| Activase® (alteplase, recombinant) is a tissue plasminogen activator (or t-PA) approved for the treatment of acute myocardial infarction (heart attack), acute ischemic stroke (blood clots in the brain) within three hours of the onset of symptoms, and acute massive pulmonary embolism (blood clots in the lungs). TNKase® (tenecteplase) is a modified form of t-PA approved for the treatment of acute myocardial infarction (heart attack). Cathflo® Activase® (alteplase, recombinant) is a t-PA approved in adult and pediatric patients for the restoration of function to central venous access devices that have become occluded due to a blood clot. |
|
| Pulmozyme |
Raptiva |
| Pulmozyme® (dornase alfa, recombinant) is an inhalation solution approved, in combination with standard therapies, for the management of cystic fibrosis patients to improve pulmonary function. |
|
| Raptiva® (efalizumab) is a humanized
anti-CD11a antibody approved
for the treatment of chronic moderate-
to-severe plaque psoriasis
in adults age 18 or older who are
candidates for systemic therapy
or phototherapy. |
|
